

首页 期刊概况 编委会 期刊内容 特邀审稿 投稿指南 出版发行

406~411.荧光磁性纳米粒子与PSA单链抗体复合探针对前列腺癌的靶向显像和治疗[J].韩月东,崔大祥,宦 怡,李智铭,刘贺亮,宋 华,刘 彬,杜 彤,高 峰,贺 蓉.中国肿瘤生物治疗杂志,2008,15(5)

荧光磁性纳米粒子与PSA单链抗体复合探针对前列腺癌的靶向显像和治疗 点此下载全文

韩月东 崔大祥 宦 怡 李智铭 刘贺亮 宋 华 刘 彬 杜 彤 高 峰 贺 蓉

第四军医大学 西京医院 放射医学科, 西安 710032; 上海交通大学 微纳科技研究院 生物纳米工程研究室,微纳制造技术国家重点实验室,薄膜微细教育部重点实验室,上海 200240; 第四军医大学 西京医院 放射医学科, 西安 710032; 上海交通大学 微纳科技研究院 生物纳米工程研究室,微纳制造技术国家重点实验室,薄膜微细教育部重点实验室,上海 200240; 第四军医大学 西京医院 泌尿外科,西安 710032; 上海交通大学 微纳科技研究院 生物纳米工程研究室,微纳制造技术国家重点实验室,薄膜微细教育部重点实验室,上海 200240; 上海交通大学 微纳科技研究院 生物纳米工程研究室,微纳制造技术国家重点实验室,进渡微细教育部重点实验室,进渡微细教育部重点实验室,进渡微细教育部重点实验室,进海 200240; 上海交通大学 微纳科技研究院 生物纳米工程研究室,微纳制造技术国家重点实验室,上海 200240; 上海交通大学 微纳科技研究院 生物纳米工程研究室,微纳制造技术国家重点实验室,上海 200240; 上海交通大学 微纳科技研究院 生物纳米工程研究室,微纳制造技术国家重点实验室,薄膜微细教育部重点实验室,排膜微细教育部重点实验室,上海 200240; 上海交通大学 微纳科技研究院 生物纳米工程研究室,微纳制造技术国家重点实验室,薄膜微细教育部重点实验室,上海 200240

基金项目: 国家重点基础研究发展(973)计划资助项目(No.2005CB723400 G); 国家高技术研究发展(863)计划重点项目(No. 2007AA022004); 国家自然科学基金资助项目(No. 30771075; No.30672147); 浦江人才计划项目(No.06PJ14049); 上海市纳米专项基金项目(No. 0752nm024); 上海市科委基金资助项目(NO.072112006 6)

DOI: 10.3872/j.issn.1007-385X.2008.5.002

摘要:

摘 要 目的: 研究荧光磁性纳米粒子与前列腺癌特异性抗原(prostate cancer specific antigen,PSA)单链抗体片段结合的复合纳米探针作为前列腺癌核磁共振靶向显像剂与治疗剂的可行性。方法: 荧光磁性纳米粒子(FMCNPs)与前列腺癌特异性单链抗体片段(ScFv)桥联制备成复合纳米探针(FMCNPs ScFv),应用高分辨电镜、荧光光谱仪与磁强度计进行鉴定。将FMCNPs ScFv与前列腺癌LNCaP细胞共培养,观察其进入癌细胞的靶向性: 采用MTT法评价复合纳米探针的细胞毒性。建立裸鼠前列腺癌细胞移植模型,进行免疫组化和病理学鉴定;荷前列腺癌裸鼠尾静脉注射复合纳米探针,采用荧光成像系统观察纳米探针在裸鼠体内的分布消除过程;利用核磁共振观察复合纳米探针肿瘤靶向显像效果;给予体外磁场照射(100 W功率)30 min,观察肿瘤体积的变化。结果: 成功制备复合纳米探针所CNPs ScFv;细胞培养实验显示复合纳米探针能够进入前列腺癌细胞质;在显像浓度范围内复合纳米探针细胞毒性很低,不影响细胞增殖。成功制备裸鼠前列腺癌组整型。荧光成像系统显示复合纳米探针快速地在裸鼠各重要器官分布,并逐渐集中于肿瘤部位;核磁共振显示纳米探针在24 h内能够清晰显示前列腺癌图像;体外磁场照射4 d后,注射复合纳米探针的裸鼠肿瘤组织生长显著慢于对照裸鼠的肿瘤组织(P <0.05)。结论:制备的复合纳米探针所CNPs ScFv能有效地靶向前列腺癌组织,可用于前列腺癌的核磁共振成像,也能用于体外磁场作用下的肿瘤治疗。

关键词: 前列腺癌 荧光磁性纳米粒子 前列腺癌特异性抗原单链抗体 纳米探针 核磁共振成像 靶向治疗

Nanocomoposite probes composed of fluorescent magnetic nanoparticles and PSA ScFv antibody for targeted imaging and therapy of prostate cancer Download Fulltext

HAN Yue dong CUI Da xiang HUAN Yi LI Zhi ming LIU He liang SONG Hua LIU Bing DU Tong GAO Feng HE Rong

Department of Radio medicine, Xijing Hospital, Fourth Military Medical University, Xi¹ an 710032, China; Department of Bio Nano Science and Engineering, National Key Laboratory of Micro Nano Fabrication Technology, Institute of Micro Nano Science and Technology, Shanghai Jiaotong University, Shanghai 200240; Department of Radio medicine, Xijing Hospital, Fourth Military Medical University, Xi¹ an 710032, China; Department of Bio Nano Science and Engineering, National Key Laboratory of Micro Nano Fabrication Technology, Institute of Micro Nano Science and Technology, Shanghai Jiaotong University, Shanghai 200240; Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi¹an, 710032, China; Department of Bio Nano Science and Engineering, National Key Laboratory of Micro Nano Fabrication Technology, Institute of Micro Nano Science and Technology, Shanghai Jiaotong University, Shanghai 200240; Department of Bio Nano Science and Engineering, National Key Laboratory of Micro Nano Fabrication Technology, Institute of Micro Nano Science and Engineering, National Key Laboratory of Micro Nano Fabrication Technology, Institute of Micro Nano Science and Technology, Shanghai Jiaotong University, Shanghai 200240; Department of Bio Nano Science and Engineering, National Key Laboratory of Micro Nano Fabrication Technology, Institute of Micro Nano Science and Technology, Shanghai Jiaotong University, Shanghai Jiaotong U

Fund Project: Supported by the Major State Basic Research Development Program (973) of China (No.2005CB723400 G); the National High Tecnology Research and Development Program (863) of China (No.2007AA022004); the National Natural Science Foundation of China (No.30771075; No.30672147)

Abstract:

Abstract Objective: To investigate the feasibility of targeted imaging and therapy of prostate cancer using nanocomposite probes composed of fluorescent magnetic nanoparticles (FMCNPs) and single chain Fv (ScFv) antibody specific for gama seminoprotein. Methods: The nanocomposite probes (FMCNPs ScFv) were prepared by conjugating fluorescent magnetic nanoparticles with singlegama chain Fv antibody specific gama seminoprotein, and were characterized by high resolution transmission electron microscopy, fluorescent spectrum and magnetic spectrum. Nanocomposite probes were incubated with prostate cancer LNCaP cells, and the targeting results of nanocomposite probes were observed by fluorescent microscopy. The cytotoxicity effect of the nanocomposite probes was measured by MTT. Nude mice models of prostate cancer were established and identified by immunohistochemistry method. The nanocomposite probes were injected into nude mice via tall vein. The distribution of nanocomposite probes in the nude mice was observed by Micro animal imaging system, targeted imaging of the prostate cancer was observed by MR instrument. The nude mice with prostate cancer were irradiated with 100 W magnetic field for 30 min, and the changes of tumor sizes were observed. Results: The FMCNPs ScFv nanocomposite probes were successfully prepared. Nanocomposite probes entered into the cytoplasm of cancer cells and exhibited low cytotoxicity effect. Nude mice model with prostate cancer were successfully fabricated; the nanocomposite probes distributed quickly in the main organs of mice, and gradually concentrated on the tumor tissues within 24 h. MR images showed that the tumor images were gradually enhanced from 6 h to 24 h after injection of the nanocomposite probe. Four days after magnetic irradiation, the tumors in the nude mice grew slower compared with the control nude mice (P<0.05). Conclusion: The nanocomposite probes composed of FMCNPs and ScFv antibody can be used for targeted imaging of prostate cancer by MRI instrument and for therapy under in vitro magnetic field.

<u>antigen</u> <u>nanocompsoite probe</u> <u>targeting imaging</u> <u>targeting therapy</u>

查看全文 查看/发表评论 下载PDF阅读器

Copyright © Biother.Org™ All Rights Reserved; ISSN: 1007-385X CN 31-1725 主管单位:中国科学技术协会 主办单位:中国免疫学会、中国抗癌学会地址:上海市杨浦区翔殷路800号 邮政编码: 200433 京ICP备06011393号-2本系统由北京勤云科技发展有限公司设计